Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

A lean thinking approach to improve efficiency in providing immune-chemotherapy injection in out-patient service: A pivotal study

Andrea Carmeni, Demetria Romeo, Francesco Di Raimondo et al. Nov 03, 2025 pp. 7926-7926 10.1182/blood-2025-7926

Abstract Background The administration of chemotherapy in a hospital setting is intrinsically complex, involving a highly regulated chain of...

IDH2 mutant hematopoietic stem and progenitor cells promote endothelial niche remodeling

Edgardo Franco, Christina Kaszuba, Benjamin Rodems et al. Nov 03, 2025 pp. 1408-1408 10.1182/blood-2025-1408

Abstract Myelodysplastic syndromes (MDS) are a group of hematologic disorders, characterized by a block in differentiation of myeloid-lineag...

A comparative analysis of epigenetic age acceleration across distinct hematopoietic clones in hematologic diseases

Atsushi Marumo, Arda Durmaz, Aashray Mandala et al. Nov 03, 2025 pp. 4945-4945 10.1182/blood-2025-4945

Abstract Studiesbased on the Horvath methylation clock have demonstrated that biological age, estimated based on methylation levels at speci...

Patient perspectives on the burden of hypereosinophilic syndrome: Results from the Phase 3 natron interview sub-study

Princess Ogbogu, Piotr Lacwik, Piotr Kuna et al. Nov 03, 2025 pp. 4465-4465 10.1182/blood-2025-4465

Abstract Background Hypereosinophilic syndrome (HES) encompasses a group of rare disorders characterized by persistently high levels of eosi...

Molecular characterization of patients (pts) with myeloproliferative neoplasms treated with INCA033989 demonstrates selective targeting of CALR mutant hematopoietic cells

Bethan Psaila, Jyoti Nangalia, Jason Gotlib et al. Nov 03, 2025 pp. 71-71 10.1182/blood-2025-71

Abstract Background: Essential thrombocythemia (ET) and myelofibrosis (MF) are driven by mutations in calreticulin (mutCALR) in ~30% of pati...

QTc prolongation in allogeneic bone marrow transplantation: Assessing cardiac complications and survival outcomes in the modern era

Mark deBettencourt, Timothy O'Connor, Kayéromi Gomez et al. Nov 03, 2025 pp. 2416-2416 10.1182/blood-2025-2416

Abstract Purpose/Objectives:QT interval prolongation is clinically relevant due to increased risk of sudden cardiac death from Torsades de P...

Effect of duffy status on patients with breast cancer receiving cyclin-dependent kinase 4/6 inhibitors

Grace Ferri, Corina Beiner Martinez, Jose Acevedo et al. Nov 03, 2025 pp. 6170-6170 10.1182/blood-2025-6170

Abstract Purpose: To improve clinical decision-making in patients with breast cancer receiving CDK 4/6 inhibitors, we examined Duffy status...

Single cell protein interactomes by the proximity network assay

Filip Karlsson, Michele Simonetti, Christina Galonska et al. Nov 03, 2025 pp. 6570-6570 10.1182/blood-2025-6570

Abstract Cellular function depends on dynamic interactions and nanoscale spatial organisation of proteins. While transcriptomic and proteomi...

Phase ib study to assess the efficacy and safety of epcoritamab in relapsed or refractory post-transplant lymphoproliferative disorder

Timothy Voorhees, Rina Welkie, Hemalatha Rao et al. Nov 03, 2025 pp. 8240-8240 10.1182/blood-2025-8240

Abstract Background Post-transplant lymphoproliferative disorders (PTLD) represent a heterogeneous group of immune-deficiency related lympho...

Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT

Iman Abou Dalle, Luuk Gras, Linda Koster et al. Nov 03, 2025 pp. 6357-6357 10.1182/blood-2025-6357

Abstract Background: High-dose chemotherapy with melphalan followed by autologous hematopoietic cell transplantation (auto-HCT) remains the...

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji et al. Nov 03, 2025 pp. 2072-2072 10.1182/blood-2025-2072

Abstract Introduction The topline results from the randomized phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for...

Rituximab beats the odds in ITP? a 5-year national showdown against TPO-ras

Zaid Zahid, Mohammad Salameh, Jamil Nazzal et al. Nov 03, 2025 pp. 735-735 10.1182/blood-2025-735

Abstract Background The two commonly used second-line strategies for Immune thrombocytopenia (ITP) include rituximab, an anti-CD20 monoclona...

National trends in deep vein thrombosis (DVT) hospitalizations: Comparing in-hospital outcomes in patients with versus without lymphoma (2016-2022)

Muhammad Usman, Najam Gohar, Hammad Ismail et al. Nov 03, 2025 pp. 8053-8053 10.1182/blood-2025-8053

Abstract Introduction: Deep vein thrombosis (DVT) is a potentially life-threatening complication in patients with cancer. Among cancers, lym...

Superior real-world outcomes of lisocabtagene maraleucel in chronic lymphocytic leukemia

Jennifer Huang, Jenna Voutsinas, Niranjan Khaire et al. Nov 03, 2025 pp. 798-798 10.1182/blood-2025-798

Abstract Introduction: Lisocabtagene maraleucel (liso-cel) was approved in the United States for the treatment of CLL in 3/2024 for patients...

Dynamic evolution of minimal residual disease and normal plasma cells following autologous stem cell transplantation in multiple myeloma

Qirui Bai, Wenqiang Yan, Xiaoqi Qin et al. Nov 03, 2025 pp. 2241-2241 10.1182/blood-2025-2241

Abstract High-dose melphalan followed by autologous stem cell transplantation (ASCT) has became a cornerstone of standard therapy for newly...

Single-cell analysis and functional profiling reveal galectin-3–driven reprogramming of the tumor immune microenvironment in transformed follicular lymphoma

Xiaohui Wang, Xianhuo Wang, Huilai Zhang Nov 03, 2025 pp. 5033-5033 10.1182/blood-2025-5033

Abstract Background: Histological transformation of follicular lymphoma (tFL) represents an aggressive subtype characterized by a complex an...

Hodgkin lymphoma-driven hemophagocytic lymphohistiocytosis (HLH) in a predominantly hispanic cohort: A multicenter analysis of clinical features and treatment outcomes

Mitchell Boshkos, Kelly Meza, Humberto Nieves Jimenez et al. Nov 03, 2025 pp. 2980-2980 10.1182/blood-2025-2980

Abstract Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome characterized by profound i...

Artificial intelligence‑driven virtual tumor board enhances precision care in Acute Myeloid Leukemia (AML)

David Swoboda, Jiasheng Wang, Thomas Kehoe et al. Nov 03, 2025 pp. 5176-5176 10.1182/blood-2025-5176

Abstract Background and Aims Acute Myeloid Leukemia (AML) presents significant diagnostic and therapeutic challenges due to rapidly evolving...

The CD33 SNP rs3865444 modulates the association of clonal hematopoiesis with Alzheimer's disease

Christopher Arends, Shaneice Mitchell, Ademar Bynum et al. Nov 03, 2025 pp. 1401-1401 10.1182/blood-2025-1401

Abstract Introduction: Clonal hematopoiesis of indeterminate potential (CHIP) is associated with an increased risk of several age-related pr...

Safety and efficacy of blinatumomab for EBV viremia and PTLD following allogeneic hematopoietic stem cell transplantation

Yunchao Su, Song Xue, Wei Ma et al. Nov 03, 2025 pp. 6061-6061 10.1182/blood-2025-6061

Abstract Background The incidence of Epstein-Barr virus (EBV) reactivation after allogeneic hematopoietic stem cell transplantation (allo-HS...

From co-occurrence to mutual exclusivity: Long read single-cell rnaseq atlas of healthy human bone marrow unveils RNA isoform landscape

Elana Thieme, Erica Arriaga-Gomez, Stanley Lee et al. Nov 03, 2025 pp. 6133-6133 10.1182/blood-2025-6133

Abstract Hematopoietic cell types achieve distinct functions despite sharing the same genome, in part through the expression of alternative...

Pociredir, a novel oral once-daily fetal hemoglobin inducer: Results from the Phase 1b pioneer study in adult participants with severe sickle cell disease and hydroxyurea intolerance or unresponsiveness

Sheinei Alan, Johnny Mahlangu, Michael Birrer et al. Nov 03, 2025 pp. 1157-1157 10.1182/blood-2025-1157

Abstract Introduction. Increased expression of fetal hemoglobin (HbF) can counteract hemoglobin S polymer formation in sickle cell disease (...

Trends in mortality from thrombotic microangiopathies with underlying cardiovascular comorbidities as a contributing cause in the United States (1999–2020)

Ritwik Dey, Yagnapriya Chirrareddy, Manas Pustake et al. Nov 03, 2025 pp. 7997-7997 10.1182/blood-2025-7997

Abstract Background: Thrombotic microangiopathies (TMAs) are life-threatening disorders often complicated by cardiovascular comorbidities. D...

First-in-human phase I trial combining radiopharmaceutical therapy (RPT) using a 90y-anti-CD25 monoclonal antibody (Mab) with total marrow and lymphoid irradiation (TMLI) in relapsed or refractory (R/R) acute leukemia

Jeffrey Wong, Monzr M. Al Malki, Dongyun Yang et al. Nov 03, 2025 pp. 508-508 10.1182/blood-2025-508

Abstract Purpose: Patients with R/R acute leukemia who undergo allogeneic hematopoietic cell transplantation (alloHCT) have a dismal prognos...

Real-world characteristics, treatment modifications, and outcomes for patients with Acute Myeloid Leukemia (AML) receiving hypomethylating agents (HMA) + venetoclax (VEN) as first-line treatment (1L)

Amer Zeidan, Yuexi Wang, Rebekah Yu et al. Nov 03, 2025 pp. 8176-8176 10.1182/blood-2025-8176

Abstract Background: Older patients with acute myeloid leukemia (AML), those with multiple comorbidities, and/or poor performance status are...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page